{
  "id": 14416513,
  "title": "Rakovina Therapeutics Secures Exclusivity on Optimized kt-5000 Lead Profile from Variational AI",
  "url": "https://urgent.news/2026/10/14/rakovina-therapeutics-secures-exclusivity-on-optimized-kt-5000-lead",
  "topic": "ai",
  "section": "AI",
  "published": "2026-10-14T09:34:12.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/rakovina-therapeutics-secures-exclusivity-on-optimized-kt-5000-lead-profile-from-variational-ai"
  },
  "original_language": "en",
  "account": null,
  "summary": "Agreement provides Rakovina exclusive access to its optimized kt-5000 target profile and extends AI-powered lead optimization through year-end at no additional cost VANCOUVER, British Columbia, Oct. 14, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery,…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}